Compare Ginkgo Bioworks Holdings Inc (DNA) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Recursion Pharmaceuticals Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.51 (market cap $505.73M), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 3.6× Ginkgo Bioworks Holdings Inc's market cap. Which is the better fit depends on your goals.
| DNA | RXRX | |
|---|---|---|
Market Cap | $505.73M | $1.81B |
Sector | Health | Health |
52-Week High | $16.14 | $6.79 |
52-Week Low | $5.48 | $2.84 |
Enterprise Value | $607.68M | $1.33B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
